Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The age-adjusted International Prognostic Index assessed before salvage therapy with ICE (ifosfamide, carboplatin, etoposide) predicts outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). Patients can be stratified according to this index into favorable and unfavorable cohorts. Subsequently we attempted to determine if the cell of origin as determined by immunohistochemistry would predict outcome, as it had in the first-line setting. However, none of the molecular markers, which are prognostic in first-line therapy, nor immunohistochemical classification by cell of origin, relate to survival outcome of DLBCL patients in the second-line setting, implying that dose intensification of therapy can overcome the prognostic import of these unfavourable risk factors.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume17
Issue numberSUPPL. 4
DOIs
StatePublished - May 1 2006
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Stem Cell Transplantation
Drug Therapy
Salvage Therapy
Ifosfamide
Carboplatin
Etoposide
Immunohistochemistry
Survival
Therapeutics

Keywords

  • Autologous stem cell transplantation
  • Diffuse large B-cell lymphoma (DLBCL)
  • DNA microarray
  • ICE (ifosfamide, carboplatin, etoposide) regimen
  • Prognostic factors
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{ac02fdb798db4be9ac8f7ca7fb9aaba6,
title = "Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation",
abstract = "The age-adjusted International Prognostic Index assessed before salvage therapy with ICE (ifosfamide, carboplatin, etoposide) predicts outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). Patients can be stratified according to this index into favorable and unfavorable cohorts. Subsequently we attempted to determine if the cell of origin as determined by immunohistochemistry would predict outcome, as it had in the first-line setting. However, none of the molecular markers, which are prognostic in first-line therapy, nor immunohistochemical classification by cell of origin, relate to survival outcome of DLBCL patients in the second-line setting, implying that dose intensification of therapy can overcome the prognostic import of these unfavourable risk factors.",
keywords = "Autologous stem cell transplantation, Diffuse large B-cell lymphoma (DLBCL), DNA microarray, ICE (ifosfamide, carboplatin, etoposide) regimen, Prognostic factors, Rituximab",
author = "Craig Moskowitz",
year = "2006",
month = "5",
day = "1",
doi = "10.1093/annonc/mdj998",
language = "English (US)",
volume = "17",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation

AU - Moskowitz, Craig

PY - 2006/5/1

Y1 - 2006/5/1

N2 - The age-adjusted International Prognostic Index assessed before salvage therapy with ICE (ifosfamide, carboplatin, etoposide) predicts outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). Patients can be stratified according to this index into favorable and unfavorable cohorts. Subsequently we attempted to determine if the cell of origin as determined by immunohistochemistry would predict outcome, as it had in the first-line setting. However, none of the molecular markers, which are prognostic in first-line therapy, nor immunohistochemical classification by cell of origin, relate to survival outcome of DLBCL patients in the second-line setting, implying that dose intensification of therapy can overcome the prognostic import of these unfavourable risk factors.

AB - The age-adjusted International Prognostic Index assessed before salvage therapy with ICE (ifosfamide, carboplatin, etoposide) predicts outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). Patients can be stratified according to this index into favorable and unfavorable cohorts. Subsequently we attempted to determine if the cell of origin as determined by immunohistochemistry would predict outcome, as it had in the first-line setting. However, none of the molecular markers, which are prognostic in first-line therapy, nor immunohistochemical classification by cell of origin, relate to survival outcome of DLBCL patients in the second-line setting, implying that dose intensification of therapy can overcome the prognostic import of these unfavourable risk factors.

KW - Autologous stem cell transplantation

KW - Diffuse large B-cell lymphoma (DLBCL)

KW - DNA microarray

KW - ICE (ifosfamide, carboplatin, etoposide) regimen

KW - Prognostic factors

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=33646895826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646895826&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj998

DO - 10.1093/annonc/mdj998

M3 - Article

C2 - 16702184

AN - SCOPUS:33646895826

VL - 17

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 4

ER -